Source - RNS
RNS Number : 4558O
Arix Bioscience Plc
17 May 2018
 

 

 

Arix Bioscience Plc

 

Results of Annual General Meeting

 

LONDON, 17 May, 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Thursday 17 May 2018 at 11am (BST). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 20 April 2018 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 15 were passed as ordinary resolutions. Resolutions 16 to 19 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' report and the accounts for the Company for the year ended 31 December 2017

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

2

To approved the Directors' Remuneration Report for the year ended 31 December 2017

50,988,886

90.12

5,591,495

9.88

56,580,381

41.98%

4,020

3

To re‐elect Dr Joseph Anderson as a Director

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

4

To re‐elect Professor Sir Christoher Evans as a Director

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

5

To re‐elect Dr Franz Humer as a Director

51,655,214

91.29

4,929,188

8.71

56,584,402

41.99%

0

6

To re‐elect Lord John Hutton of Furness as a Director

54,810,619

96.87

1,773,783

3.13

56,584,402

41.99%

0

7

To re‐elect Professor Trevor Jones as a Director

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

8

To re‐elect Jonathan Peacock as a Director

54,526,217

96.36

2,058,185

3.64

56,584,402

41.99%

0

9

To re‐elect James Rawlingson as a Director

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

10

To re‐elect David U'Prichard as a Director

55,183,865

97.53

1,399,000

2.47

56,582,865

41.99%

1,537

11

To elect Meghan FitzGerald as a Director

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

12

To elect Giles Kerr as a Director

56,582,865

100.00

0

0.00

56,582,865

41.99%

1,537

13

To re‐appoint PwC LLP as auditors of the Company

55,185,402

97.53

1,399,000

2.47

56,584,402

41.99%

0

14

To authorise the Audit & Risk Committee of the Company to fix the remuneration of  the auditors

56,584,402

100.00

0

0.00

56,584,402

41.99%

0

15

To authorise the Directors to allot shares

55,618,631

100.00

2,198

0.00

55,620,829

41.27%

963,573

16

To authorise the Directors to disapply statutory pre‐ emption rights in respect of 5% of the Company's issued share capital

53,013,611

95.32

2,605,020

4.68

55,618,631

41.27%

965,771

17

To authorise the Directors to disapply statutory pre‐ emption rights in respect of an additional 5% of the Company's issued share capital

51,614,611

92.80

4,004,020

7.20

55,618,631

41.27%

965,771

18

To authorise the Company to buy back shares

54,215,987

97.48

1,403,929

2.52

55,619,916

41.27%

964,486

19

To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice

56,581,832

100.00

2,570

0.00

56,584,402

41.99%

0

 

 

Notes:

1.      Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2.      A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3.      The number of voting shares in issue at 6:00 p.m. on 15 May 2018 was 134,764,018 (the "Share Capital"). The Company does not hold any shares in treasury.

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at www.hemscott.com/nsm.do

 

ENDS

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Robert Lyne, Company Secretary

+44 (0) 20 7290 1055

 

Charlotte Parry, Investor Relations Manager

+44 (0)20 7290 1072

[email protected]

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

[email protected]

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

 

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

 

For further information, please visit www.arixbioscience.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFKODBDBKDOPD

Related Charts

Arix Bioscience (ARIX)

0.00p (0.00%)
delayed 14:57PM